Lumos Pharma Inc. (LUMO) |
|
13.86 0.04 (0.29%)
|
10-01 09:38 |
|
Open: |
14.295 |
Pre. Close: |
13.82 |
|
High:
|
13.86 |
Low:
|
13.86 |
|
Volume:
|
7 |
Market Cap:
|
115M |
|
|
|
|
Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
14.1 - 14.179 |
14.179 - 14.251 |
|
Low:
|
13.304 - 13.406 |
13.406 - 13.5 |
|
Close:
|
13.928 - 14.08 |
14.08 - 14.219 |
|
Technical analysis |
as of: 2020-09-30 4:43:50 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 17.21  One year: 18.10 |
| Support: |
Support1: 13.51 Support2: 11.24 |
| Resistance: |
Resistance1: 14.74 Resistance2: 15.50 |
| Pivot: |
14.36 |
| Moving Average: |
MA(5): 13.89 MA(20): 14.48
MA(100): 14.65 MA(250): 7.82 |
| MACD: |
MACD(12,26): -0.28 Signal(9): -0.21 |
| Stochastic oscillator: |
%K(14,3): 21.48 %D(3): 18.16 |
| RSI: |
RSI(14): 43.41 |
| 52-week: |
High: 17.50 Low: 0.82 Change(%): 1054.3 |
| Average Vol(K): |
3-Month: 2802 10-Days: 1657 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.LUMO has closed above bottom band by 32.9%. Bollinger Bands are 43.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to LUMO's normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 13 Aug 2020
Lumos Pharma, Inc. (LUMO) Tops Q2 EPS by 6c - StreetInsider.com
Thu, 13 Aug 2020
Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities - GlobeNewswire
Thu, 13 Aug 2020
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q2 2020 Results - Earnings Call Transcript - Seeking Alpha
Tue, 28 Jul 2020
Analyst Rating: Will Lumos Pharma Inc (LUMO) Stock Outperform the Market? - InvestorsObserver
Mon, 27 Jul 2020
Lumos Pharma Announces Sale of Priority Review Voucher - GlobeNewswire
Wed, 10 Jun 2020
Is Lumos Pharma, Inc. (LUMO) A Good Stock To Buy? - Yahoo Finance
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
n/a |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
n/a |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
8 |
| Shares Float (M) |
|
|
% Held by Insiders
|
13.00 |
|
% Held by Institutions
|
39.99 |
|
Shares Short (K)
|
192 |
|
Shares Short P. Month (K)
|
190 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-1.103 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-8 |
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
|
|
Price to Cash Flow
|
-14.03 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
